News Releases

Date Title and Summary
Toggle Summary gammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association
ROCKAWAY, N.J. , Nov. 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has been issued a National Code Number (CNK) in Belgium.  CNK numbers are unique product code identifiers
Toggle Summary electroCore to Participate at Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum
ROCKAWAY, N.J. , Nov. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger , will be conducting one-on-ones at the Canaccord Genuity MedTech and Diagnostics and
Toggle Summary electroCore Announces Third Quarter 2022 Financial Results
Third quarter 2022 revenue grew 33% over third quarter 2021 Company to host a conference call and webcast today, November 3, 2022 at 4:30 pm EDT ROCKAWAY, N.J. , Nov. 03, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced third
Toggle Summary electroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLC
ROCKAWAY, N.J. , Nov. 01, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore Sapphire™, the first and only FDA-cleared, non-invasive device to treat and prevent multiple types of headache pain via the vagus
Toggle Summary electroCore to Announce Third Quarter 2022 Financial Results on November 3
ROCKAWAY, N.J. , Oct. 27, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the third quarter ended September 30, 2022 , after the close of the market on Thursday, November 3, 2022
Toggle Summary gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury
Pre-clinical trial demonstrates ability of nVNS to decrease amount of brain injury, decrease anxiety and improve motor function post injury ROCKAWAY, N.J. , Oct. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced data
Toggle Summary electroCore Provides Select Third Quarter 2022 Financial Guidance
ROCKAWAY, N.J. , Oct. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary financial guidance for the third quarter of 2022.  Financial Guidance Preliminary unaudited financial
Toggle Summary electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents
Four patents issued expanding claims related to delivery of nVNS and other therapies using mobile devices ROCKAWAY, N.J. , Sept. 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and
Toggle Summary Electrocore Announces Date for Fiscal Year 2022 Annual Meeting and Deadlines for Stockholder Proposals
ROCKAWAY, N.J. , Sept. 20, 2022 (GLOBE NEWSWIRE) --  electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine company, today announced its plans to hold its fiscal year 2022 annual meeting of stockholders (the “2022 Annual Meeting”) on Friday, December 2, 2022 .
Toggle Summary gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Reduces Symptoms of Acute Withdrawal in Patients with Opioid Use Disorder
ROCKAWAY, N.J. , Sept. 07, 2022 (GLOBE NEWSWIRE) --  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed manuscript,  Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological